Jul 01,2014

Nemaura Medical announces licensing deal with DB Pharma (Jersey) Ltd

Nemaura Medical announces licensing deal with DB Pharma (Jersey) Ltd., for its unique non-invasive wireless continuous glucose monitoring Watch for the UK and Ireland. DB Pharma (Jersey) Ltd. has the sole and exclusive rights to market its CGM Watch in the UK and Republic of Ireland once the product receives CE approval which is anticipated for 2015.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 05,2014

Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, and DexCom, Inc (NASDAQ: DXCM), the leader in continuous glucose monitoring technology, today announced their intention to allow information from Dexcom's 5th generation CGM system to be identified, received and displayed on Insulet's new Bluetooth-enabled Personal Diabetes Manager, currently in development. This project expands upon the initial agreement announced in June to enable the Dexcom mobile app platform to integrate data from Insulet's OmniPod System.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 24,2014

Medtronic showcases smartphone-enabled continuous glucose monitoring

Medtronic has developed a Bluetooth-enabled continuous glucose monitoring system for patients with diabetes, that will connect to an iOS app, Medtronic Global Program Marketing Manager Samantha Katz announced from the stage at Health 2.0 in Santa Clara, California. On the app, which will work with a future generation of Medtronic's existing sensor, users will be able to set their own custom ranges and be alerted by a push notification or an alarm when their glucose goes over or under a certain level.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 20,2014

Dexcom Share, a smartphone-connected CGM charging cradle, gets FDA clearance

Dexcom Share, a cradle device that will allow users to send data from a Dexcom continuous glucose monitor to multiple smartphones, has received 510(k) clearance from the FDA. The system is designed to help parents and caregivers remotely track the glucose of a child, elderly parent, or spouse when the diabetes patient is at home or stationary. “Dexcom Share represents a significant advance in diabetes care by allowing people with diabetes to share important glucose information with their loved ones from afar,” Terrance H. Gregg, Chief Executive Office of Dexcom, said in a statement.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 03,2014

FDA Approves Dexcom Software with Artificial Pancreas Algorithm

Dexcom announced today that the U.S. Food and Drug Administration (FDA) has approved new software for the Dexcom G4® PLATINUM CGM. The new Software 505 features the same advanced algorithm as used in artificial pancreas research around the world. The software will impact the performance of the Dexcom G4 PLATINUM.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 01,2014

Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength

The research aims to assess feasibility of overnight closed-loop therapy in young children with type 1 diabetes and contrast closed loop using diluted versus standard insulin strength. In this feasibility study, closed-loop therapy maintained good overnight glucose control with tendency towards reduced hypoglycemia and reduced glucose variability using diluted insulin.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
May 25,2020

Bayer and WaveForm Technologies Inc. to Provide CGM Solutions for Patients in China

Bayer announced today a commercial agreement with WaveForm Technologies Inc. (WaveForm), a wholly owned subsidiary of AgaMatrix Holdings LLC and developer of novel products for continuous glucose monitoring (CGM) based in Wilsonville, Oregon, U.S. The collaboration aims to provide innovative glucose monitoring solutions to patients and physicians in China by integrating WaveForm’s novel and proprietary technologies with Bayer’s extensive experience and know-how in diabetes management. Under the terms of the agreement WaveForm will be responsible for obtaining marketing authorization for its Cascade CGM system while Bayer will be responsible for commercialization, distribution and sales, as well as customer support.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review

This review summarizes recent evidence supporting an association between CGM-derived TIR and microvascular complications among patients with T2DM.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

This real-world study aimed to assess the impact on glycated hemoglobin (HbA1c) of flash glucose monitoring (FreeStyle Libre) use in adults with type 2 diabetes managed with basal insulin.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 05,2022

Optimal Data Collection Period for Continuous Glucose Monitoring to Assess Long-Term Glycemic Control: Revisited

It is not clear how the short-term continuous glucose monitoring (CGM) sampling time could influence the bias in estimating long-term glycemic control. This study sought to investigate the relation between sampling time and bias in the estimates.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM